基于Markov模型的华佗救心丸治疗冠状动脉粥样硬化性心脏病的药物经济学评价  

Pharmacoeconomic Evaluation of Huatuo Jiuxin Pills in the Treatment of Coronary Heart Disease based on Markov Model

作　　者：孙阳 钟蔚仪 张诗韵 张洁[1] 倪彗彤 周乃彤[1] SUN Yang;ZHONG Wei-Yi;ZHANG Shi-Yun;ZHANG Jie;NI Hui-Tong;ZHOU Nai-Tong(West China College of Pharmacy,Sichuan University,Chengdu 610041,China;West China College of Stomatology,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西药学院 [2]四川大学华西口腔医学院

出　　处：《中国药物经济学》2024年第12期20-24,共5页China Journal of Pharmaceutical Economics

摘　　要：目的评价华佗救心丸联合西药常规方案对比西药常规方案治疗冠状动脉粥样硬化性心脏病的经济性,为临床用药和相关决策提供经济学证据和参考。方法以卫生体系为研究角度,采用决策树模型对华佗救心丸联合西药常规方案对比西药常规方案治疗冠状动脉粥样硬化性心脏病进行成本-效用分析,并进行敏感性分析。结果模型模拟两种方案治疗30年的健康结果,华佗救心丸联合西药常规方案累积治疗成本和健康产出分别为170813.29元和19.43QALYs;西药常规方案累积治疗成本和健康产出分别为168273.52元和18.39QALYs;与西药常规方案相比,华佗救心丸联合西药常规方案的增量成本-效用比(ICUR)为2452.39元/QALY,小于1倍人均GDP(89358元),因此华佗救心丸联合西药常规方案更具经济性。单因素敏感性分析结果表明基础分析结果较稳健。结论华佗救心丸联合西药常规方案相比于西药常规方案治疗冠状动脉粥样硬化性心脏病更具成本-效果优势。Objective To evaluate the economics of Huatuo Jiuxin Pills combined with conventional western medicine treatment compared with conventional western medicine treatment in the treatment of coronary heart disease,and to provide economic evidence and reference for the clinical use of medication and related decision-making.Methods From the perspective of health system,decision tree model was used to analyze the cost-effectiveness and sensitivity of Huatuo Jiuxin Pill combined with conventional western medicine in the treatment of coronary atherosclerotic heart disease.Results Simulating the health outcomes of the two treatments,the cumulative treatment costs and health outputs were 170813.29 yuan and 19.43 QALYs for the Huatuo Jiuxin Pills combined with the conventional western medicine treatment,respectively;the cumulative treatment costs and health outputs for the conventional western medicine were 168273.52 yuan and 18.39 QALYs,respectively.This study used the gross domestic product per capita(GDP)as the willingness to pay(WTP)threshold,and the incremental cost-utility ratio(ICUR)was 2452.39 yuan/QALY,which was lower than China's per capita GDP(in 2023)of 89358.00 yuan.Single factor sensitivity analysis showed that the results of basic analysis were robust.Conclusion The combination of Huatuo lifesaving pill and conventional Western medicine has more cost-effectiveness advantages than conventional Western medicine in the treatment of coronary heart disease.

关 键 词：MARKOV模型 华佗救心丸 冠状动脉粥样硬化性心脏病 成本-效用分析 

分 类 号：R541.4[医药卫生—心血管疾病] R956[医药卫生—内科学]